Skip to main content
Top
Published in: International Journal of Clinical Oncology 3/2013

01-06-2013 | Original Article

First indicators of relapse in breast cancer: evaluation of the follow-up program at our hospital

Authors: Yoshinari Ogawa, Katsumi Ikeda, Tetsuo Izumi, Shiho Okuma, Makoto Ichiki, Tetsuro Ikeya, Jyunya Morimoto, Yukio Nishiguchi, Teruyuki Ikehara

Published in: International Journal of Clinical Oncology | Issue 3/2013

Login to get access

Abstract

Background

Guidelines for breast cancer patient follow-up have not been widely adopted in Japan. To assess our intensive follow-up program, we evaluated first relapse and its indicators in patients with breast cancer.

Patients

Of 964 patients, 126 relapsed and 43 died in the median follow-up term of 45 months. Follow-ups were scheduled every 6–12 months for imaging and tumor marker (TM) evaluation.

Results

Of 126 relapsed patients, 30 (23.8%) had symptoms of relapse. First indicators of relapse in 96 asymptomatic patients were physical examination in 24 patients (19%); imaging, 57 patients (45.3%); and TMs, 15 patients (11.9%). The most sensitive indicators were physical examination for local relapse, ultrasonography for regional lymph nodes, scintigraphy for bone, computed tomography for lung, and TMs for liver metastasis. During intensive follow-up, 43% of relapsed patients were identified by symptoms or physical examination. These patients had poor prognosis compare to patients identified by imaging or TMs in overall survival and post-relapse survival (p = 0.009 and 0.019, respectively). In all 964 patients, the relapse rates for stage I, IIA, IIB, and III tumors were 7.4, 7.9, 19.9, and 43.5%, respectively. The percentage of first relapse detected by imaging or TMs for stage I, IIA, IIB, and III were 4.7, 5.1, 11.8, and 19.8%, respectively. The cost of our follow-up program for 10 years was approximately 290,000 yen per patient.

Conclusion

A routine intensive follow-up program involving imaging and evaluation of TMs in all patients has low efficacy and high expenditure.
Literature
1.
go back to reference Schwartz D, Billingsley K, Wallner K (2000) Follow-up care for cancer: making the benefits equal the cost. Oncology (Williston Park) 14:1493–1498 Schwartz D, Billingsley K, Wallner K (2000) Follow-up care for cancer: making the benefits equal the cost. Oncology (Williston Park) 14:1493–1498
2.
go back to reference Cooper GS, Johnson CC, Lamerato L et al (2006) Use of guideline recommended follow-up care in cancer survivors: routine or diagnostic indications? Med Care 44:590–594PubMedCrossRef Cooper GS, Johnson CC, Lamerato L et al (2006) Use of guideline recommended follow-up care in cancer survivors: routine or diagnostic indications? Med Care 44:590–594PubMedCrossRef
3.
go back to reference Whiting J, Sano T, Saka M et al (2006) Follow-up of gastric cancer: a review. Gastric Cancer 9:74–81PubMedCrossRef Whiting J, Sano T, Saka M et al (2006) Follow-up of gastric cancer: a review. Gastric Cancer 9:74–81PubMedCrossRef
4.
go back to reference Papagrigoriadis S (2007) Follow-up of patients with colorectal cancer: the evidence is in favour but we are still in need of a protocol. Int J Surg 5:120–128PubMedCrossRef Papagrigoriadis S (2007) Follow-up of patients with colorectal cancer: the evidence is in favour but we are still in need of a protocol. Int J Surg 5:120–128PubMedCrossRef
5.
go back to reference Calman L, Beaver K, Hind D et al (2011) Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis. J Thorac Oncol 6:1993–2004PubMedCrossRef Calman L, Beaver K, Hind D et al (2011) Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis. J Thorac Oncol 6:1993–2004PubMedCrossRef
6.
go back to reference Pivot X, Asmar L, Hortobagy GN et al (2000) A retrospective study of first indicators of breast cancer recurrence. Oncology 58:185–190PubMedCrossRef Pivot X, Asmar L, Hortobagy GN et al (2000) A retrospective study of first indicators of breast cancer recurrence. Oncology 58:185–190PubMedCrossRef
7.
go back to reference Joseph E, Hyacinthe M, Lyman GH et al (1998) Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg 5:522–528CrossRef Joseph E, Hyacinthe M, Lyman GH et al (1998) Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg 5:522–528CrossRef
8.
go back to reference The GIVIO investigators (1994) Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 271:1587–1592CrossRef The GIVIO investigators (1994) Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 271:1587–1592CrossRef
9.
go back to reference Del Turco MR, Palli D, Cariddi A et al (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. JAMA 271:1593–1597CrossRef Del Turco MR, Palli D, Cariddi A et al (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. JAMA 271:1593–1597CrossRef
10.
go back to reference Khatcheressian JK, Wolff AC, Smith TJ et al (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24:5091–5097PubMedCrossRef Khatcheressian JK, Wolff AC, Smith TJ et al (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24:5091–5097PubMedCrossRef
11.
go back to reference Mille D, Roy T, Carrere MO et al (2000) Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol 18:1718–1724PubMed Mille D, Roy T, Carrere MO et al (2000) Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol 18:1718–1724PubMed
12.
go back to reference Schapira DV (1993) Breast cancer surveillance—a cost-effective strategy. Breast Cancer Res Treat 25:107–111PubMedCrossRef Schapira DV (1993) Breast cancer surveillance—a cost-effective strategy. Breast Cancer Res Treat 25:107–111PubMedCrossRef
13.
go back to reference The Japanese Breast Cancer Society (2005) General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 12:s1–s14CrossRef The Japanese Breast Cancer Society (2005) General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 12:s1–s14CrossRef
15.
go back to reference Pennant M, Takwoingi Y, Pennant L et al (2010) A systemic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 14:1–103 Pennant M, Takwoingi Y, Pennant L et al (2010) A systemic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 14:1–103
16.
go back to reference Chu CH, Lin SC, Shih SC et al (2003) Fatty metamorphosis of the liver in patients with breast cancer: possible associated factors. World J Gastroenterol 9:1618–1620PubMed Chu CH, Lin SC, Shih SC et al (2003) Fatty metamorphosis of the liver in patients with breast cancer: possible associated factors. World J Gastroenterol 9:1618–1620PubMed
17.
go back to reference Akhondi-Meybodi M, Mortazavy-Zadah MR, Hashemian Z (2011) Incidence and risk factors of non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer. Arab J Gastroenterol 12:34–36PubMedCrossRef Akhondi-Meybodi M, Mortazavy-Zadah MR, Hashemian Z (2011) Incidence and risk factors of non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer. Arab J Gastroenterol 12:34–36PubMedCrossRef
18.
go back to reference Clevert DA, Jung EM, Stock KF et al (2009) Evaluation of malignant liver tumors: biphasic MS-CT versus quantitative contrast harmonic imaging ultrasound. Z Gastroenterol 47:1195–1202PubMedCrossRef Clevert DA, Jung EM, Stock KF et al (2009) Evaluation of malignant liver tumors: biphasic MS-CT versus quantitative contrast harmonic imaging ultrasound. Z Gastroenterol 47:1195–1202PubMedCrossRef
19.
go back to reference Jung EM, Clevert DA, Scherver AG et al (2007) Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study. World J Gastroenterol 13:6356–6364PubMedCrossRef Jung EM, Clevert DA, Scherver AG et al (2007) Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study. World J Gastroenterol 13:6356–6364PubMedCrossRef
20.
go back to reference Gerber S, Ollivier L, Ala-Eddine C et al (2011) Brain metastasis of breast cancer; imaging evaluation. Bull Cancer 98:399–407 [in French] Gerber S, Ollivier L, Ala-Eddine C et al (2011) Brain metastasis of breast cancer; imaging evaluation. Bull Cancer 98:399–407 [in French]
21.
go back to reference Palli D, Russo A, Saieva C et al (1999) Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of randomized trial. JAMA 281:1586PubMedCrossRef Palli D, Russo A, Saieva C et al (1999) Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of randomized trial. JAMA 281:1586PubMedCrossRef
23.
go back to reference Smid M, Wang Y, Zhang Y et al (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108–3114PubMedCrossRef Smid M, Wang Y, Zhang Y et al (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108–3114PubMedCrossRef
24.
go back to reference Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746PubMed Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746PubMed
25.
go back to reference Shibuta K, Ueo H, Furusawa H et al (2011) The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. Breast Cancer 18:292–298 Shibuta K, Ueo H, Furusawa H et al (2011) The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. Breast Cancer 18:292–298
26.
go back to reference de Ruijter TC, Veeck J, de Hoon JPJ et al (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137:183–192PubMedCrossRef de Ruijter TC, Veeck J, de Hoon JPJ et al (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137:183–192PubMedCrossRef
27.
go back to reference Fulford LG, Reis-Filho JS, Ryder K et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9:R4PubMedCrossRef Fulford LG, Reis-Filho JS, Ryder K et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9:R4PubMedCrossRef
28.
go back to reference Voduc KD, Cheang MC, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691PubMedCrossRef Voduc KD, Cheang MC, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691PubMedCrossRef
29.
go back to reference Chacón RD, Costanzo MV (2010) Triple-negative breast cancer. Breast Cancer Res 12 (suppl 2):S3 Chacón RD, Costanzo MV (2010) Triple-negative breast cancer. Breast Cancer Res 12 (suppl 2):S3
Metadata
Title
First indicators of relapse in breast cancer: evaluation of the follow-up program at our hospital
Authors
Yoshinari Ogawa
Katsumi Ikeda
Tetsuo Izumi
Shiho Okuma
Makoto Ichiki
Tetsuro Ikeya
Jyunya Morimoto
Yukio Nishiguchi
Teruyuki Ikehara
Publication date
01-06-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-012-0401-0

Other articles of this Issue 3/2013

International Journal of Clinical Oncology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine